2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

Journal of the American College of Cardiology

Volumn 70, Issue 14, 2017, Pages 1785-1822

  Lloyd Jones, Donald M ^a   Morris, Pamela B ^a   Ballantyne, Christie M ^a   Birtcher, Kim K ^a   Daly, David D ^a   DePalma, Sondra M ^a   Minissian, Margo B ^a   Orringer, Carl E ^a   Smith, Sidney C ^a  

^a NONE

Author keywords

ACC Expert Consensus Decision Pathway; ASCVD; bile acid sequestrants; cholesterol; dyslipidemia; ezetimibe; LDL C; lipids; PCSK9 inhibitors; statins

Indexed keywords

ALIROCUMAB; ATORVASTATIN; BILE ACID SEQUESTRANT; BOCOCIZUMAB; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; ENZYME INHIBITOR; EVOLOCUMAB; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MIPOMERSEN; NICOTINIC ACID; PHYTOSTEROL; PITAVASTATIN; PLACEBO; PRAVASTATIN; PROPROTEIN CONVERTASE 9 INHIBITOR; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; WARFARIN; HYPOCHOLESTEROLEMIC AGENT; SEQUESTERING AGENT;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ADD ON THERAPY; ALGORITHM; ARTHRALGIA; ARTICLE; BACKACHE; BLOATING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CONSTIPATION; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPHAGIA; ESOPHAGUS OBSTRUCTION; FAMILIAL HYPERCHOLESTEROLEMIA; FECES IMPACTION; FLU LIKE SYNDROME; GENETIC SCREENING; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLUENZA; INJECTION SITE REACTION; INTESTINE OBSTRUCTION; LIMB PAIN; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MYALGIA; NAUSEA; PANCREATITIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLICATION; RHINOPHARYNGITIS; RISK MANAGEMENT; SECONDARY PREVENTION; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CARDIOLOGY; CHEMOPROPHYLAXIS; CONSENSUS; CONSENSUS DEVELOPMENT; CORONARY ARTERY DISEASE; HYPERCHOLESTEROLEMIA; MEDICATION THERAPY MANAGEMENT; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PROCEDURES; UNITED STATES;

ANTICHOLESTEREMIC AGENTS; CARDIOLOGY; CHEMOPREVENTION; CHOLESTEROL, LDL; CONSENSUS; CORONARY ARTERY DISEASE; ENZYME INHIBITORS; EZETIMIBE; HUMANS; HYPERCHOLESTEROLEMIA; MEDICATION THERAPY MANAGEMENT; SEQUESTERING AGENTS; UNITED STATES;

EID: 85028886889     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.07.745     Document Type: Article

References (59)

1. Lloyd-Jones, D.M., Morris, P.B., Ballantyne, C.M., et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 68 (2016), 92–125.
2. Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
3. Ridker, P.M., Revkin, J., Amarenco, P., et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med 376 (2017), 1527–1539.
4. ODYSSEY outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab. Available at: https://clinicaltrials.gov/ct2/show/NCT01663402. (Accessed 27 February 2016)
5. The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2). Available at: https://clinicaltrials.gov/ct2/show/NCT01975389?term=spire+2+bococizumab&rank=1. (Accessed 27 February 2016)
6. Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
7. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). Available at: https://clinicaltrials.gov/ct2/show/NCT01764633?term=evolocumab+fourier&rank=1. (Accessed 27 February 2016)
8. Bohula, E.A., Morrow, D.A., Giugliano, R.P., et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. J Am Coll Cardiol 69 (2017), 911–921.
9. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
10. Goff, D.C. Jr., Lloyd-Jones, D.M., Bennett, G., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2935–2959.
11. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 100:Suppl 2 (2014), ii1–ii67.
12. Downs, J.R., O'Malley, P.G., Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med 163 (2015), 291–297.
13. US Preventive Services Task Force. Draft Recommendation Statement: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication. Available at: http://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement175/statin-use-in-adults-preventive-medication1. (Accessed 18 January 2016)
14. Baigent, C., Blackwell, L., Emberson, J., et al., Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
15. LaRosa, J.C., Grundy, S.M., Waters, D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005), 1425–1435.
16. Landray, M.J., Haynes, R., Hopewell, J.C., et al., HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371 (2014), 203–212.
17. Robinson, J.G., Farnier, M., Krempf, M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1489–1499.
18. Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1500–1509.
19. Ridker, P.M., Tardif, J.C., Amarenco, P., et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med 376 (2017), 1517–1526.
20. Robinson, J.G., Huijgen, R., Ray, K., et al. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol 68 (2016), 2412–2421.
21. Eckel, R.H., Jakicic, J.M., Ard, J.D., et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2960–2984.
22. Jacobson, T.A., Maki, K.C., Orringer, C.E., et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol 9 (2015), S1–S122.e1.
23. Rosenson, R.S., Baker, S.K., Jacobson, T.A., et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 8 (2014), S58–S71.
24. Guyton, J.R., Bays, H.E., Grundy, S.M., et al. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 8 (2014), S72–S81.
25. Ahmad, Z., Statin intolerance. Am J Cardiol 113 (2014), 1765–1771.
26. Jacobson, T.A., Ito, M.K., Maki, K.C., et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol 9 (2015), 129–169.
27. Miller, M., Stone, N.J., Ballantyne, C., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123 (2011), 2292–2333.
28. Schandelmaier, S., Briel, M., Saccilotto, R., et al. Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev, 6, 2017, CD009744.
29. Mora, S., Rifai, N., Buring, J.E., et al. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem 55 (2009), 888–894.
30. Martin, S.S., Blaha, M.J., Elshazly, M.B., et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol 62 (2013), 732–739.
31. Descamps, O., Tomassini, J.E., Lin, J., et al. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. Atherosclerosis 240 (2015), 482–489.
32. Blom, D.J., Hala, T., Bolognese, M., et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 370 (2014), 1809–1819.
33. Perak, A.M., Ning, H., de Ferranti, S.D., et al. Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype. Circulation 134 (2016), 9–19.
34. Khera, A.V., Won, H.H., Peloso, G.M., et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 67 (2016), 2578–2589.
35. Aggarwal, S., Loomba, R.S., Arora, R.R., Efficacy of colesevelam on lowering glycemia and lipids. J Cardiovasc Pharmacol 59 (2012), 198–205.
36. Goldberg, A.C., Hopkins, P.N., Toth, P.P., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5 (2011), S1–S8.
37. Cuchel, M., Bruckert, E., Ginsberg, H.N., et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 35 (2014), 2146–2157.
38. Wiegman, A., Gidding, S.S., Watts, G.F., et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 36 (2015), 2425–2437.
39. Gidding, S.S., Champagne, M.A., de Ferranti, S.D., et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation 132 (2015), 2167–2192.
40. Rader, D.J., Kastelein, J.J., Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129 (2014), 1022–1032.
41. Bhoj, V.G., Sachais, B.S., Lipoprotein apheresis. Curr Atheroscler Rep, 17, 2015, 39.
42. Tavazzi, L., Maggioni, A.P., Marchioli, R., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008), 1231–1239.
43. Kjekshus, J., Apetrei, E., Barrios, V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007), 2248–2261.
44. Ridker, P.M., Danielson, E., Fonseca, F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
45. Feinstein, M.J., Jhund, P., Kang, J., et al. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. Eur J Heart Fail 17 (2015), 434–441.
46. Baigent, C., Landray, M.J., Reith, C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377 (2011), 2181–2192.
47. Fellstrom, B.C., Jardine, A.G., Schmieder, R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009), 1395–1407.
48. Bateman, B.T., Hernandez-Diaz, S., Fischer, M.A., et al. Statins and congenital malformations: cohort study. BMJ, 350, 2015, h1035.
49. Merck and Co Inc. Zetia Prescribing Information. Revised August 2013. Available at: http://www.merck.com/product/usa/pi_circulars/z/zetia/zetia_pi.pdf. (Accessed 27 February 2016)
50. Sanofi Aventis US LLC. Praluent Prescribing Information. Revised October 2015. Available at: http://products.sanofi.us/praluent/praluent.pdf. (Accessed 27 February 2016)
51. Amgen Inc. Repatha Prescribing Information. Revised August 2015. Available at: http://pi.amgen.com/united_states/repatha/repatha_pi_hcp_english.pdf. (Accessed 27 February 2016)
52. Giugliano, R.P., Mach, F., Zavitz, K., et al. Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. Clin Cardiol 40 (2017), 59–65.
53. Par Pharmaceutical Companies Inc. Questran (Cholestyramine) Prescribing Information. Revised February 2013. Available at: http://medlibrary.org/lib/rx/meds/questran-1/. (Accessed 27 February 2016)
54. Daiichi Sankyo Inc. Welchol Prescribing Information. Revised January 2014. Available at: http://dsi.com/prescribing-information-portlet/getDocument?product=WC&inline=true. (Accessed 27 February 2016)
55. Pharmacia and Upjohn Co Division of Pfizer Inc. Colestid Prescribing Information. Revised May 2014. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=593. (Accessed 27 February 2016)
56. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251 (1984), 351–364.
57. Superko, H.R., Greenland, P., Manchester, R.A., et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol 70 (1992), 135–140.
58. Kastle Therapeutics LLC. Kynamro Prescribing Information. Available at: http://www.kynamro.com/media/pdfs/Kynamro_Prescribing_information.pdf. (Accessed 11 April 2017)
59. Aegerion Pharmaceuticals Inc. Juxtapid Prescribing Information. Available at: http://www.juxtapidpro.com/prescribing-information. (Accessed 11 April 2017)